| Q90253550 | A Review of Clinical Pharmacokinetic and Pharmacodynamic Profiles of Select Antiretrovirals: Focus on Differences among Chinese Patients |
| Q36966025 | Advances in pharmacogenomics of antiretrovirals: an update. |
| Q38818898 | Aspirin responsiveness changes in obese patients following bariatric surgery |
| Q35743488 | Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. |
| Q42972297 | CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients |
| Q34558478 | Clinical application of the paraspinal erector approach for spinal canal decompression in upper lumber burst fractures |
| Q40100880 | Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals |
| Q40131806 | Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients. |
| Q61820505 | Comparative Tissue Factor Pathway Inhibitor Release Potential of Heparins |
| Q36582696 | Critical pathways: the role of pharmacy today and tomorrow. |
| Q61820482 | Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid |
| Q33343793 | Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies |
| Q37688260 | Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy |
| Q42130690 | Disulfiram metabolite S-methyl-N,N-diethylthiocarbamate quantitation in human plasma with reverse phase ultra performance liquid chromatography and mass spectrometry. |
| Q36788409 | Drug interactions between proton pump inhibitors and antiretroviral drugs. |
| Q28548638 | Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection |
| Q92038347 | Effect of rilpivirine on the pharmacokinetics of methadone in HIV-Infected Chinese patients |
| Q45855929 | Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia |
| Q46506742 | Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population |
| Q46866962 | Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir |
| Q61820510 | Global Anticoagulant Effects of a Novel Sulfated Pentomanan Oligosaccharide Mixture |
| Q36125023 | Global HIV/AIDS Clinical and Translational Pharmacology |
| Q44366007 | Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use. |
| Q37318371 | Host proteome research in HIV infection. |
| Q40118824 | Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus. |
| Q44678428 | Influence of different anticoagulant agents on fibrinopeptide a generation |
| Q43588770 | Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist |
| Q35738878 | Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. |
| Q37699049 | Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism |
| Q37045335 | Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir. |
| Q61820509 | Molecular and biochemical profiling of a heparin-derived oligosaccharide, C3 |
| Q47428416 | Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan |
| Q34081535 | Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. |
| Q46955645 | Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. |
| Q35829744 | Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults |
| Q37528417 | Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. |
| Q35213469 | Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice |
| Q53260414 | Pharmacodynamics and pharmacokinetics of C3, a heparin-derived oligosaccharide mixture, in non-human primates. |
| Q61820497 | Pharmacogenomics and HIV pharmacotherapy |
| Q37419542 | Pharmacogenomics of CYP3A: considerations for HIV treatment |
| Q45330127 | Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications |
| Q36826482 | Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir |
| Q37140177 | Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients. |
| Q28069383 | Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals |
| Q46880890 | Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients |
| Q38868951 | Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans |
| Q36575497 | Recent advances in management of the HIV/HCV coinfected patient |
| Q37254474 | Research in women and special populations |
| Q34495619 | Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. |
| Q42222138 | Single-tablet, once-daily treatment regimens for HIV. |
| Q28271545 | Studies on the effect of calcium in interactions between heparin and heparin cofactor II using surface plasmon resonance |
| Q90329919 | Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid |
| Q48581408 | The blood-brain barrier accessibility of a heparin-derived oligosaccharides C3. |
| Q35855545 | The impact of herbal drug use on adverse drug reaction profiles of patients on antiretroviral therapy in zimbabwe |
| Q37720765 | Therapeutic drug monitoring in highly active antiretroviral therapy. |
| Q35061983 | Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders. |
| Q51553332 | Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients. |